Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh(KR:950210)
â‚©3,820.00-25.00 (-1.55%)
KR:950210
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh financials statements
â‚©3,820.00
At close:-25.00 (-1.55%)
Want to see KR:950210 full AI Analyst Report?
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh (950210) Ratios
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Ratios
KR:950210's free cash flow for Q4 2024 was ₩-13.92B. For the 2024 fiscal year, KR:950210's free cash flow was decreased by ₩-8.53B and operating cash flow was ₩-5.39B. See a summary of the company’s cash flow.
| Ratios | Jun 25 | Jun 25 | Jun 23 | Jun 22 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.27 | 0.75 | 1.72 | 7.45 | 2.31 |
| Quick Ratio | 1.11 | 0.52 | 1.59 | 7.40 | 2.26 |
| Cash Ratio | 0.70 | 0.11 | 1.50 | 6.43 | 0.93 |
| Solvency Ratio | 0.19 | -0.25 | -0.08 | -2.97 | 0.15 |
| Operating Cash Flow Ratio | -0.33 | -0.39 | -0.33 | -1.10 | -0.45 |
| Short-Term Operating Cash Flow Coverage | -0.49 | -0.69 | -1.00 | -28.69 | -1.83 |
| Net Current Asset Value | â‚© -27.20B | â‚© -125.45B | â‚© 54.13B | â‚© 241.69B | â‚© 116.11B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.14 | 0.13 | 0.01 | 0.12 |
| Debt-to-Equity Ratio | 0.35 | 0.24 | 0.20 | 0.01 | 0.19 |
| Debt-to-Capital Ratio | 0.26 | 0.20 | 0.17 | 0.01 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.07 | 0.05 | 0.08 | 0.00 | 0.10 |
| Financial Leverage Ratio | 1.81 | 1.71 | 1.62 | 1.16 | 1.65 |
| Debt Service Coverage Ratio | 0.28 | -0.69 | -0.57 | -128.29 | 0.29 |
| Interest Coverage Ratio | -8.83 | -13.52 | -8.48 | -6303.28 | 1.09 |
| Debt to Market Cap | 0.16 | 0.27 | 0.17 | 0.00 | 0.15 |
| Interest Debt Per Share | 2525.91 | 1880.82 | 1615.27 | 71.02 | 1449.80 |
| Net Debt to EBITDA | 0.86 | -1.47 | 4.18 | 1.28 | -3.69 |
| Profitability Margins | |||||
| Gross Profit Margin | -167.77% | -62.76% | -76.74% | 0.00% | 79.03% |
| EBIT Margin | 80.62% | -359.06% | -6868.65% | 0.00% | -707.84% |
| EBITDA Margin | 232.80% | -233.42% | -4505.69% | 0.00% | 6496.03% |
| Operating Profit Margin | -470.14% | -359.06% | -9111.19% | 0.00% | 639.51% |
| Pretax Profit Margin | 27.38% | -471.95% | -7936.63% | 0.00% | -1294.78% |
| Net Profit Margin | 155.64% | -350.95% | -4777.60% | 0.00% | 10855.89% |
| Continuous Operations Profit Margin | 29.12% | -471.37% | -7995.94% | 0.00% | -1766.40% |
| Net Income Per EBT | 568.42% | 74.36% | 60.20% | 100.38% | -838.43% |
| EBT Per EBIT | -5.82% | 131.44% | 87.11% | 177.28% | -202.47% |
| Return on Assets (ROA) | 3.00% | -12.34% | -4.63% | -42.31% | 2.37% |
| Return on Equity (ROE) | 5.45% | -21.07% | -7.50% | -49.18% | 3.90% |
| Return on Capital Employed (ROCE) | -11.65% | -15.70% | -11.10% | -25.94% | 0.17% |
| Return on Invested Capital (ROIC) | -9.77% | -13.80% | -10.21% | -25.76% | 0.16% |
| Return on Tangible Assets | 4.05% | -16.92% | -5.70% | -48.67% | 2.82% |
| Earnings Yield | 2.52% | -23.56% | -6.20% | -30.73% | 3.09% |
| Efficiency Ratios | |||||
| Receivables Turnover | 14.29 | 5.00 | 1.76 | 0.00 | 1.22 |
| Payables Turnover | 6.57 | 7.98 | 0.53 | 1.47 | 0.07 |
| Inventory Turnover | 1.43 | 1.29 | 0.07 | 1.79 | 0.00 |
| Fixed Asset Turnover | 0.04 | 0.06 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.02 | 0.04 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.19 | 6.45 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 225.83 | 310.46 | 4949.05 | -44.05 | 72179.58 |
| Days of Sales Outstanding | 25.55 | 72.96 | 207.43 | 0.00 | 299.33 |
| Days of Inventory Outstanding | 255.86 | 283.22 | 5425.54 | 203.47 | 76850.32 |
| Days of Payables Outstanding | 55.58 | 45.71 | 683.92 | 247.52 | 4970.07 |
| Operating Cycle | 281.41 | 356.18 | 5632.97 | 203.47 | 77149.65 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -904.22 | -940.32 | -799.18 | -763.90 | -1002.96 |
| Free Cash Flow Per Share | -1581.41 | -1039.67 | -1264.96 | -1897.30 | -2094.83 |
| Dividend Paid and CapEx Coverage Ratio | -1.34 | -9.46 | -1.72 | -0.67 | -0.92 |
| Capital Expenditure Coverage Ratio | -1.34 | -9.46 | -1.72 | -0.67 | -0.92 |
| Operating Cash Flow Coverage Ratio | -0.38 | -0.53 | -0.54 | -10.80 | -0.70 |
| Operating Cash Flow to Sales Ratio | -3.80 | -2.17 | -69.70 | 0.00 | -372.43 |
| Free Cash Flow Yield | -10.76% | -16.09% | -14.33% | -16.57% | -22.17% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 39.66 | -4.24 | -16.12 | -3.25 | 32.32 |
| Price-to-Sales (P/S) Ratio | 61.73 | 14.89 | 770.09 | 0.00 | 3509.04 |
| Price-to-Book (P/B) Ratio | 2.16 | 0.89 | 1.21 | 1.60 | 1.26 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.30 | -6.21 | -6.98 | -6.03 | -4.51 |
| Price-to-Operating Cash Flow Ratio | -16.26 | -6.87 | -11.05 | -14.99 | -9.42 |
| Price-to-Earnings Growth (PEG) Ratio | -0.24 | 0.01 | 0.06 | -0.00 | -0.30 |
| Enterprise Value Multiple | 27.38 | -7.85 | -12.91 | -2.05 | 50.32 |
| Enterprise Value | 912.21B | 477.77B | 400.88B | 423.70B | 529.06B |
| EV to EBITDA | 27.38 | -7.85 | -12.91 | -2.05 | 50.32 |
| EV to Sales | 63.75 | 18.33 | 581.77 | 0.00 | 3269.02 |
| EV to Free Cash Flow | -9.60 | -7.65 | -5.27 | -3.72 | -4.20 |
| EV to Operating Cash Flow | -16.79 | -8.45 | -8.35 | -9.23 | -8.78 |
| Tangible Book Value Per Share | 5212.73 | 5094.01 | 6352.28 | 6067.35 | 7110.68 |
| Shareholders’ Equity Per Share | 6804.94 | 7225.35 | 7306.43 | 7154.15 | 7496.51 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.06 | 0.00 | -0.01 | -0.00 | -0.36 |
| Revenue Per Share | 238.12 | 433.71 | 11.47 | 0.00 | 2.69 |
| Net Income Per Share | 370.62 | -1522.11 | -547.81 | -3518.54 | 292.35 |
| Tax Burden | 5.68 | 0.74 | 0.60 | 1.00 | -8.38 |
| Interest Burden | 0.34 | 1.31 | 1.16 | 1.00 | 1.83 |
| Research & Development to Revenue | 1.33 | 1.63 | 34.01 | 0.00 | 252.80 |
| SG&A to Revenue | 1.65 | 0.75 | 65.95 | 0.00 | -330.24 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.08 | 0.00 | 12.01 |
| Income Quality | -2.44 | 0.62 | 0.87 | 0.22 | 21.08 |
Currency in KRW
